Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)</title><author><name sortKey="Al Tawfiq, Jaffar A" sort="Al Tawfiq, Jaffar A" uniqKey="Al Tawfiq J" first="Jaffar A." last="Al-Tawfiq">Jaffar A. Al-Tawfiq</name><affiliation><nlm:aff id="AFF0001"><institution>Specialty Internal Medicine, Johns Hopkins Aramco Healthcare</institution>, Dhahran,<country>Kingdom of Saudi Arabia</country></nlm:aff></affiliation><affiliation><nlm:aff id="AFF0002"><institution>Department of Medicine, Indiana University School of Medicine</institution>, Indianapolis, IN,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A." last="Memish">Ziad A. Memish</name><affiliation><nlm:aff id="AFF0003"><institution>Department of Medicine, Ministry of Health</institution>, Riyadh,<country>Kingdom of Saudi Arabia</country></nlm:aff></affiliation><affiliation><nlm:aff id="AFF0004"><institution>Hubert Department of Global Health, Rollins School of Public Health, Emory University</institution>, Atlanta, GA,<country>USA</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27937060</idno><idno type="pmc">7103731</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103731</idno><idno type="RBID">PMC:7103731</idno><idno type="doi">10.1080/14787210.2017.1271712</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">001321</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001321</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)</title><author><name sortKey="Al Tawfiq, Jaffar A" sort="Al Tawfiq, Jaffar A" uniqKey="Al Tawfiq J" first="Jaffar A." last="Al-Tawfiq">Jaffar A. Al-Tawfiq</name><affiliation><nlm:aff id="AFF0001"><institution>Specialty Internal Medicine, Johns Hopkins Aramco Healthcare</institution>, Dhahran,<country>Kingdom of Saudi Arabia</country></nlm:aff></affiliation><affiliation><nlm:aff id="AFF0002"><institution>Department of Medicine, Indiana University School of Medicine</institution>, Indianapolis, IN,<country>USA</country></nlm:aff></affiliation></author><author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A." last="Memish">Ziad A. Memish</name><affiliation><nlm:aff id="AFF0003"><institution>Department of Medicine, Ministry of Health</institution>, Riyadh,<country>Kingdom of Saudi Arabia</country></nlm:aff></affiliation><affiliation><nlm:aff id="AFF0004"><institution>Hubert Department of Global Health, Rollins School of Public Health, Emory University</institution>, Atlanta, GA,<country>USA</country></nlm:aff></affiliation></author></analytic><series><title level="j">Expert Review of Anti-Infective Therapy</title><idno type="ISSN">1478-7210</idno><idno type="eISSN">1744-8336</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>ABSTRACT</title><p><bold>Introduction:</bold> The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an important emerging respiratory pathogen. MERS-CoV resulted in multiple hospital outbreaks within and outside the Arabian Peninsula. The disease has a high case fatality rate, with the need for a therapeutic option.</p><p><bold>Areas covered:</bold> In this review, we provide an overview of the progress in the development of therapeutic strategies for MERS. We searched PubMed, Embase, Cochrane, Scopus, and Google Scholar, using the following terms: ‘MERS’, ‘MERS-CoV’, ‘Middle East respiratory syndrome’ in combination with ‘treatment’ or ‘therapy’.</p><p><bold>Expert commentary:</bold> There are multiple agents tried <italic>in vitro</italic> and <italic>in vivo</italic>. None of these agents were used in large clinical studies. Available clinical studies are limited to the use of the combination of interferon and other agents. These clinical studies are based solely on case reports and case series. There are no prospective or randomized trials. There is a need to have prospective and randomized clinical trials for the therapy of MERS-CoV. However, this strategy might be hampered by the sporadic cases outside the large hospital outbreaks.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Al Tawfiq, Ja" uniqKey="Al Tawfiq J">JA Al-Tawfiq</name></author><author><name sortKey="Memish, Za" uniqKey="Memish Z">ZA. Memish</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Assiri, A" uniqKey="Assiri A">A Assiri</name></author><author><name sortKey="Mcgeer, A" uniqKey="Mcgeer A">A McGeer</name></author><author><name sortKey="Perl, Tm" uniqKey="Perl T">TM Perl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Al Tawfiq, Ja" uniqKey="Al Tawfiq J">JA Al-Tawfiq</name></author><author><name sortKey="Perl, Tm" uniqKey="Perl T">TM Perl</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Momattin, H" uniqKey="Momattin H">H Momattin</name></author><author><name sortKey="Mohammed, K" uniqKey="Mohammed K">K Mohammed</name></author><author><name sortKey="Zumla, A" uniqKey="Zumla A">A Zumla</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Chan, Jf" uniqKey="Chan J">JF Chan</name></author><author><name sortKey="Chan, Kh" uniqKey="Chan K">KH Chan</name></author><author><name sortKey="Kao, Ry" uniqKey="Kao R">RY Kao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Randall, Re" uniqKey="Randall R">RE Randall</name></author><author><name sortKey="Goodbourn, S" uniqKey="Goodbourn S">S Goodbourn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hart, Bj" uniqKey="Hart B">BJ Hart</name></author><author><name sortKey="Dyall, J" uniqKey="Dyall J">J Dyall</name></author><author><name sortKey="Postnikova, E" uniqKey="Postnikova E">E Postnikova</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Falzarano, D" uniqKey="Falzarano D">D Falzarano</name></author><author><name sortKey="De Wit, E" uniqKey="De Wit E">E de Wit</name></author><author><name sortKey="Martellaro, C" uniqKey="Martellaro C">C Martellaro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adedeji, Ao" uniqKey="Adedeji A">AO Adedeji</name></author><author><name sortKey="Sarafianos, Sg" uniqKey="Sarafianos S">SG Sarafianos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, Jf W" uniqKey="Chan J">JF-W Chan</name></author><author><name sortKey="Yao, Y" uniqKey="Yao Y">Y Yao</name></author><author><name sortKey="Yeung, M L" uniqKey="Yeung M">M-L Yeung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Wilde, Ah" uniqKey="De Wilde A">AH De Wilde</name></author><author><name sortKey="Jochmans, D" uniqKey="Jochmans D">D Jochmans</name></author><author><name sortKey="Posthuma, Cc" uniqKey="Posthuma C">CC Posthuma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shirato, K" uniqKey="Shirato K">K Shirato</name></author><author><name sortKey="Kawase, M" uniqKey="Kawase M">M Kawase</name></author><author><name sortKey="Matsuyama, S" uniqKey="Matsuyama S">S Matsuyama</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, L" uniqKey="Lu L">L Lu</name></author><author><name sortKey="Liu, Q" uniqKey="Liu Q">Q Liu</name></author><author><name sortKey="Zhu, Y" uniqKey="Zhu Y">Y Zhu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Wilde, Ah" uniqKey="De Wilde A">AH De Wilde</name></author><author><name sortKey="Raj, Vs" uniqKey="Raj V">VS Raj</name></author><author><name sortKey="Oudshoorn, D" uniqKey="Oudshoorn D">D Oudshoorn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Wilde, Ah" uniqKey="De Wilde A">AH De Wilde</name></author><author><name sortKey="Zevenhoven Dobbe, Jc" uniqKey="Zevenhoven Dobbe J">JC Zevenhoven-Dobbe</name></author><author><name sortKey="Van Der Meer, Y" uniqKey="Van Der Meer Y">Y van der Meer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rossignol, J F" uniqKey="Rossignol J">J-F Rossignol</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhou, N" uniqKey="Zhou N">N Zhou</name></author><author><name sortKey="Pan, T" uniqKey="Pan T">T Pan</name></author><author><name sortKey="Zhang, J" uniqKey="Zhang J">J Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pan, Q" uniqKey="Pan Q">Q Pan</name></author><author><name sortKey="De Ruiter, Pe" uniqKey="De Ruiter P">PE De Ruiter</name></author><author><name sortKey="Metselaar, Hj" uniqKey="Metselaar H">HJ Metselaar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Channappanavar, R" uniqKey="Channappanavar R">R Channappanavar</name></author><author><name sortKey="Lu, L" uniqKey="Lu L">L Lu</name></author><author><name sortKey="Xia, S" uniqKey="Xia S">S Xia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhao, J" uniqKey="Zhao J">J Zhao</name></author><author><name sortKey="Perera, Rapm" uniqKey="Perera R">RAPM Perera</name></author><author><name sortKey="Kayali, G" uniqKey="Kayali G">G Kayali</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Agrawal, As" uniqKey="Agrawal A">AS Agrawal</name></author><author><name sortKey="Ying, T" uniqKey="Ying T">T Ying</name></author><author><name sortKey="Tao, X" uniqKey="Tao X">X Tao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Qiu, H" uniqKey="Qiu H">H Qiu</name></author><author><name sortKey="Sun, S" uniqKey="Sun S">S Sun</name></author><author><name sortKey="Xiao, H" uniqKey="Xiao H">H Xiao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Falzarano, D" uniqKey="Falzarano D">D Falzarano</name></author><author><name sortKey="De Wit, E" uniqKey="De Wit E">E de Wit</name></author><author><name sortKey="Rasmussen, Al" uniqKey="Rasmussen A">AL Rasmussen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ying, T" uniqKey="Ying T">T Ying</name></author><author><name sortKey="Prabakaran, P" uniqKey="Prabakaran P">P Prabakaran</name></author><author><name sortKey="Du, L" uniqKey="Du L">L Du</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Al Tawfiq, Ja" uniqKey="Al Tawfiq J">JA Al-Tawfiq</name></author><author><name sortKey="Momattin, H" uniqKey="Momattin H">H Momattin</name></author><author><name sortKey="Dib, J" uniqKey="Dib J">J Dib</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Omrani, As" uniqKey="Omrani A">AS Omrani</name></author><author><name sortKey="Saad, Mm" uniqKey="Saad M">MM Saad</name></author><author><name sortKey="Baig, K" uniqKey="Baig K">K Baig</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khalid, I" uniqKey="Khalid I">I Khalid</name></author><author><name sortKey="Alraddadi, Bm" uniqKey="Alraddadi B">BM Alraddadi</name></author><author><name sortKey="Dairi, Y" uniqKey="Dairi Y">Y Dairi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shalhoub, S" uniqKey="Shalhoub S">S Shalhoub</name></author><author><name sortKey="Farahat, F" uniqKey="Farahat F">F Farahat</name></author><author><name sortKey="Al Jiffri, A" uniqKey="Al Jiffri A">A Al-Jiffri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Al Ghamdi, M" uniqKey="Al Ghamdi M">M Al Ghamdi</name></author><author><name sortKey="Alghamdi, Km" uniqKey="Alghamdi K">KM Alghamdi</name></author><author><name sortKey="Ghandoora, Y" uniqKey="Ghandoora Y">Y Ghandoora</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Uj" uniqKey="Kim U">UJ Kim</name></author><author><name sortKey="Won, E J" uniqKey="Won E">E-J Won</name></author><author><name sortKey="Kee, S J" uniqKey="Kee S">S-J Kee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spanakis, N" uniqKey="Spanakis N">N Spanakis</name></author><author><name sortKey="Tsiodras, S" uniqKey="Tsiodras S">S Tsiodras</name></author><author><name sortKey="Haagmans, Bl" uniqKey="Haagmans B">BL Haagmans</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khalid, M" uniqKey="Khalid M">M Khalid</name></author><author><name sortKey="Al Rabiah, F" uniqKey="Al Rabiah F">F Al Rabiah</name></author><author><name sortKey="Khan, B" uniqKey="Khan B">B Khan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Malik, A" uniqKey="Malik A">A Malik</name></author><author><name sortKey="El Masry, Km" uniqKey="El Masry K">KM El Masry</name></author><author><name sortKey="Ravi, M" uniqKey="Ravi M">M Ravi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khalid, M" uniqKey="Khalid M">M Khalid</name></author><author><name sortKey="Khan, B" uniqKey="Khan B">B Khan</name></author><author><name sortKey="Al Rabiah, F" uniqKey="Al Rabiah F">F Al Rabiah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, H" uniqKey="Lee H">H Lee</name></author><author><name sortKey="Ki, C S" uniqKey="Ki C">C-S Ki</name></author><author><name sortKey="Sung, H" uniqKey="Sung H">H Sung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ohnuma, K" uniqKey="Ohnuma K">K Ohnuma</name></author><author><name sortKey="Haagmans, Bl" uniqKey="Haagmans B">BL Haagmans</name></author><author><name sortKey="Hatano, R" uniqKey="Hatano R">R Hatano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pascal, Ke" uniqKey="Pascal K">KE Pascal</name></author><author><name sortKey="Coleman, Cm" uniqKey="Coleman C">CM Coleman</name></author><author><name sortKey="Mujica, Ao" uniqKey="Mujica A">AO Mujica</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Du, L" uniqKey="Du L">L Du</name></author><author><name sortKey="Kou, Z" uniqKey="Kou Z">Z Kou</name></author><author><name sortKey="Ma, C" uniqKey="Ma C">C Ma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Du, L" uniqKey="Du L">L Du</name></author><author><name sortKey="Zhao, G" uniqKey="Zhao G">G Zhao</name></author><author><name sortKey="Yang, Y" uniqKey="Yang Y">Y Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, Y" uniqKey="Li Y">Y Li</name></author><author><name sortKey="Wan, Y" uniqKey="Wan Y">Y Wan</name></author><author><name sortKey="Liu, P" uniqKey="Liu P">P Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jiang, L" uniqKey="Jiang L">L Jiang</name></author><author><name sortKey="Wang, N" uniqKey="Wang N">N Wang</name></author><author><name sortKey="Zuo, T" uniqKey="Zuo T">T Zuo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tang, X C" uniqKey="Tang X">X-C Tang</name></author><author><name sortKey="Agnihothram, Ss" uniqKey="Agnihothram S">SS Agnihothram</name></author><author><name sortKey="Jiao, Y" uniqKey="Jiao Y">Y Jiao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ying, T" uniqKey="Ying T">T Ying</name></author><author><name sortKey="Du, L" uniqKey="Du L">L Du</name></author><author><name sortKey="Ju, Tw" uniqKey="Ju T">TW Ju</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mou, H" uniqKey="Mou H">H Mou</name></author><author><name sortKey="Raj, Vs" uniqKey="Raj V">VS Raj</name></author><author><name sortKey="Van Kuppeveld, Fjm" uniqKey="Van Kuppeveld F">FJM van Kuppeveld</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Johnson, Rf" uniqKey="Johnson R">RF Johnson</name></author><author><name sortKey="Bagci, U" uniqKey="Bagci U">U Bagci</name></author><author><name sortKey="Keith, L" uniqKey="Keith L">L Keith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corti, D" uniqKey="Corti D">D Corti</name></author><author><name sortKey="Zhao, J" uniqKey="Zhao J">J Zhao</name></author><author><name sortKey="Pedotti, M" uniqKey="Pedotti M">M Pedotti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Luke, T" uniqKey="Luke T">T Luke</name></author><author><name sortKey="Wu, H" uniqKey="Wu H">H Wu</name></author><author><name sortKey="Zhao, J" uniqKey="Zhao J">J Zhao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raj, Vs" uniqKey="Raj V">VS Raj</name></author><author><name sortKey="Mou, H" uniqKey="Mou H">H Mou</name></author><author><name sortKey="Smits, Sl" uniqKey="Smits S">SL Smits</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, G" uniqKey="Lu G">G Lu</name></author><author><name sortKey="Hu, Y" uniqKey="Hu Y">Y Hu</name></author><author><name sortKey="Wang, Q" uniqKey="Wang Q">Q Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lambeir, A M" uniqKey="Lambeir A">A-M Lambeir</name></author><author><name sortKey="Durinx, C" uniqKey="Durinx C">C Durinx</name></author><author><name sortKey="Scharpe, S" uniqKey="Scharpe S">S Scharpé</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boonacker, E" uniqKey="Boonacker E">E Boonacker</name></author><author><name sortKey="Van Noorden, Cj" uniqKey="Van Noorden C">CJ Van Noorden</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hung, If" uniqKey="Hung I">IF Hung</name></author><author><name sortKey="To, Kk" uniqKey="To K">KK To</name></author><author><name sortKey="Lee, C K" uniqKey="Lee C">C-K Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Luke, Tc" uniqKey="Luke T">TC Luke</name></author><author><name sortKey="Kilbane, Em" uniqKey="Kilbane E">EM Kilbane</name></author><author><name sortKey="Jackson, Jl" uniqKey="Jackson J">JL Jackson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, X X" uniqKey="Wu ">-X-X Wu</name></author><author><name sortKey="Gao, H N" uniqKey="Gao H">H-N Gao</name></author><author><name sortKey="Wu, H B" uniqKey="Wu H">H-B Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kong, Lk" uniqKey="Kong L">LK Kong</name></author><author><name sortKey="Zhou, Bp" uniqKey="Zhou B">BP Zhou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mair Jenkins, J" uniqKey="Mair Jenkins J">J Mair-Jenkins</name></author><author><name sortKey="Saavedra Campos, M" uniqKey="Saavedra Campos M">M Saavedra-Campos</name></author><author><name sortKey="Baillie, Jk" uniqKey="Baillie J">JK Baillie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arabi, Ym" uniqKey="Arabi Y">YM Arabi</name></author><author><name sortKey="Arifi, Aa" uniqKey="Arifi A">AA Arifi</name></author><author><name sortKey="Balkhy, Hh" uniqKey="Balkhy H">HH Balkhy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kapoor, M" uniqKey="Kapoor M">M Kapoor</name></author><author><name sortKey="Pringle, K" uniqKey="Pringle K">K Pringle</name></author><author><name sortKey="Kumar, A" uniqKey="Kumar A">A Kumar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arabi, Y" uniqKey="Arabi Y">Y Arabi</name></author><author><name sortKey="Balkhy, H" uniqKey="Balkhy H">H Balkhy</name></author><author><name sortKey="Hajeer, Ah" uniqKey="Hajeer A">AH Hajeer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alshukairi, An" uniqKey="Alshukairi A">AN Alshukairi</name></author><author><name sortKey="Khalid, I" uniqKey="Khalid I">I Khalid</name></author><author><name sortKey="Ahmed, Wa" uniqKey="Ahmed W">WA Ahmed</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Drosten, C" uniqKey="Drosten C">C Drosten</name></author><author><name sortKey="Meyer, B" uniqKey="Meyer B">B Meyer</name></author><author><name sortKey="Muller, Ma" uniqKey="Muller M">MA Müller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Corman, Vm" uniqKey="Corman V">VM Corman</name></author><author><name sortKey="Albarrak, Am" uniqKey="Albarrak A">AM Albarrak</name></author><author><name sortKey="Omrani, As" uniqKey="Omrani A">AS Omrani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Park, Wb" uniqKey="Park W">WB Park</name></author><author><name sortKey="Perera, Rapm" uniqKey="Perera R">RAPM Perera</name></author><author><name sortKey="Choe, Pg" uniqKey="Choe P">PG Choe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Arabi, Ym" uniqKey="Arabi Y">YM Arabi</name></author><author><name sortKey="Hajeer, Ah" uniqKey="Hajeer A">AH Hajeer</name></author><author><name sortKey="Luke, T" uniqKey="Luke T">T Luke</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Long, Y" uniqKey="Long Y">Y Long</name></author><author><name sortKey="Xu, Y" uniqKey="Xu Y">Y Xu</name></author><author><name sortKey="Wang, B" uniqKey="Wang B">B Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Auyeung, T" uniqKey="Auyeung T">T Auyeung</name></author><author><name sortKey="Lee, J" uniqKey="Lee J">J Lee</name></author><author><name sortKey="Lai, W" uniqKey="Lai W">W Lai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, N" uniqKey="Lee N">N Lee</name></author><author><name sortKey="Allen Chan, Kc" uniqKey="Allen Chan K">KC Allen Chan</name></author><author><name sortKey="Hui, Ds" uniqKey="Hui D">DS Hui</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Belouzard, S" uniqKey="Belouzard S">S Belouzard</name></author><author><name sortKey="Millet, Jk" uniqKey="Millet J">JK Millet</name></author><author><name sortKey="Licitra, Bn" uniqKey="Licitra B">BN Licitra</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dyall, J" uniqKey="Dyall J">J Dyall</name></author><author><name sortKey="Coleman, Cm" uniqKey="Coleman C">CM Coleman</name></author><author><name sortKey="Hart, Bj" uniqKey="Hart B">BJ Hart</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Uyeki, Tm" uniqKey="Uyeki T">TM Uyeki</name></author><author><name sortKey="Erlandson, Kj" uniqKey="Erlandson K">KJ Erlandson</name></author><author><name sortKey="Korch, G" uniqKey="Korch G">G Korch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sakamoto, S" uniqKey="Sakamoto S">S Sakamoto</name></author><author><name sortKey="Tanaka, H" uniqKey="Tanaka H">H Tanaka</name></author><author><name sortKey="Morimoto, S" uniqKey="Morimoto S">S Morimoto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Modjarrad, K" uniqKey="Modjarrad K">K Modjarrad</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Expert Rev Anti Infect Ther</journal-id><journal-id journal-id-type="iso-abbrev">Expert Rev Anti Infect Ther</journal-id><journal-id journal-id-type="publisher-id">IERZ</journal-id><journal-id journal-id-type="publisher-id">ierz20</journal-id><journal-title-group><journal-title>Expert Review of Anti-Infective Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-7210</issn><issn pub-type="epub">1744-8336</issn><publisher><publisher-name>Taylor & Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27937060</article-id><article-id pub-id-type="pmc">7103731</article-id><article-id pub-id-type="publisher-id">1271712</article-id><article-id pub-id-type="doi">10.1080/14787210.2017.1271712</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)</article-title><alt-title alt-title-type="running-authors">J. A. AL-TAWFIQ AND Z. A. MEMISH</alt-title><alt-title alt-title-type="running-title">EXPERT REVIEW OF ANTI-INFECTIVE THERAPY</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Al-Tawfiq</surname><given-names>Jaffar A.</given-names></name><xref ref-type="aff" rid="AFF0001"><sup>a</sup></xref><xref ref-type="aff" rid="AFF0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Memish</surname><given-names>Ziad A.</given-names></name><xref ref-type="aff" rid="AFF0003"><sup>c</sup></xref><xref ref-type="aff" rid="AFF0004"><sup>d</sup></xref><xref ref-type="corresp" rid="AN0001"></xref></contrib><aff id="AFF0001"><label>a</label><institution>Specialty Internal Medicine, Johns Hopkins Aramco Healthcare</institution>, Dhahran,<country>Kingdom of Saudi Arabia</country></aff><aff id="AFF0002"><label>b</label><institution>Department of Medicine, Indiana University School of Medicine</institution>, Indianapolis, IN,<country>USA</country></aff><aff id="AFF0003"><label>c</label><institution>Department of Medicine, Ministry of Health</institution>, Riyadh,<country>Kingdom of Saudi Arabia</country></aff><aff id="AFF0004"><label>d</label><institution>Hubert Department of Global Health, Rollins School of Public Health, Emory University</institution>, Atlanta, GA,<country>USA</country></aff></contrib-group><author-notes><corresp id="AN0001">CONTACT Ziad A. Memish <email xlink:href="Jaffar.tawfiq@jhah.com">Jaffar.tawfiq@jhah.com</email><institution>College of Medicine, Alfaisal University</institution>, <addr-line>P.O. Box 54146</addr-line>, Riyadh 11514, <country>Kingdom of Saudi Arabia</country></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>24</day><month>12</month><year>2016</year></pub-date><volume>15</volume><issue>3</issue><fpage seq="8">269</fpage><lpage>275</lpage><history><date date-type="received"><day>22</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>09</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 Informa UK Limited, trading as Taylor & Francis Group</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Informa UK Limited, trading as Taylor & Francis Group</copyright-holder><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IERZ_15_1271712.pdf"></self-uri><abstract><title>ABSTRACT</title><p><bold>Introduction:</bold> The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an important emerging respiratory pathogen. MERS-CoV resulted in multiple hospital outbreaks within and outside the Arabian Peninsula. The disease has a high case fatality rate, with the need for a therapeutic option.</p><p><bold>Areas covered:</bold> In this review, we provide an overview of the progress in the development of therapeutic strategies for MERS. We searched PubMed, Embase, Cochrane, Scopus, and Google Scholar, using the following terms: ‘MERS’, ‘MERS-CoV’, ‘Middle East respiratory syndrome’ in combination with ‘treatment’ or ‘therapy’.</p><p><bold>Expert commentary:</bold> There are multiple agents tried <italic>in vitro</italic> and <italic>in vivo</italic>. None of these agents were used in large clinical studies. Available clinical studies are limited to the use of the combination of interferon and other agents. These clinical studies are based solely on case reports and case series. There are no prospective or randomized trials. There is a need to have prospective and randomized clinical trials for the therapy of MERS-CoV. However, this strategy might be hampered by the sporadic cases outside the large hospital outbreaks.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>MERS-CoV</kwd><kwd>interferon</kwd><kwd>ribavirin</kwd><kwd>pegylated interferon</kwd><kwd>therapy</kwd></kwd-group><funding-group><funding-statement>This paper was not funded.</funding-statement></funding-group><counts><table-count count="4"></table-count><ref-count count="75"></ref-count><page-count count="7"></page-count></counts></article-meta></front><body><sec sec-type="intro" id="S0001"><label>1.</label><title>Introduction</title><p>The Middle East respiratory syndrome coronavirus (MERS-CoV) emerged as an important virus in 2012 and since then has caused multiple outbreaks in hospitals especially in the Kingdom of Saudi Arabia and outside the Arabian Peninsula [<xref rid="CIT0001">1</xref>–<xref rid="CIT0003">3</xref>]. Since the emergence of MERS-CoV, a total of 1800 cases including 640 deaths were reported by the World Health Organization (WHO) [<xref rid="CIT0004">4</xref>]. Due to the increased morbidity and mortality of MERS-CoV infection, the attention was directed toward the development of prevention strategies and the establishment of therapeutic modalities. An earlier review was based on the severe acute respiratory syndrome (SARS) experience and had suggested few possible options for the treatment of MERS-CoV infection [<xref rid="CIT0005">5</xref>]. In this review, we provide an overview of the progress in the development of therapeutic strategies for MERS.</p></sec><sec id="S0002"><label>2.</label><title>Search strategy and classification of reviewed articles</title><p>We searched PubMed, Embase, Cochrane, Scopus, and Google Scholar using the following terms: ‘MERS,’ ‘MERS-CoV,’ ‘Middle East respiratory syndrome’ in combination with ‘treatment’ or ‘therapy.’ We also reviewed the references of each article to further include other studies or reports not identified by the search. We classified the studies into the following categories: <italic>in vivo</italic> and <italic>in vitro</italic> studies, animal studies, and human case reports or case series. For clinical studies, we graded the level of the evidence based on the ‘Oxford Centre for Evidence-based Medicine’ [<xref rid="CIT0006">6</xref>].</p></sec><sec id="S0003"><label>3.</label><title><italic>In vivo</italic> and <italic>in vitro</italic> studies</title><p><italic>In vitro</italic> studies showed variable activity of various agents against MERS-CoV (<xref rid="T0001">Table 1</xref>). These agents include: interferon, ribavirin, HIV protease inhibitors (nelfinavir, ritonavir, and lopinavir).
<table-wrap id="T0001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1080/14787210.2017.1271712-T0001</object-id><label>Table 1.</label><caption><p>A summary of anti-MERS-CoV agents used <italic>in vitro</italic> and the mechanism of action.</p></caption><pmc-comment>OASIS TABLE HERE</pmc-comment><table frame="hsides" rules="groups"><colgroup><col width="1*" align="left"></col><col width="1*" align="left"></col><col width="1*" align="center"></col></colgroup><thead><tr><th align="left">Molecule</th><th align="center">Mechanism of action</th><th align="center">Reference</th></tr></thead><tbody><tr><td align="left">Interferon (IFN)</td><td align="left">Antiviral type I IFN system, a major part of the innate immune response</td><td align="center">[<xref rid="CIT0007">7</xref>–<xref rid="CIT0009">9</xref>]</td></tr><tr><td align="left">Ribavirin</td><td align="left">A nucleoside analog that is activated by host kinases to a nucleotide</td><td align="center">[<xref rid="CIT0007">7</xref>,<xref rid="CIT0010">10</xref>,<xref rid="CIT0011">11</xref>]</td></tr><tr><td align="left">Nelfinavir</td><td align="left">Protease inhibitor</td><td align="center">[<xref rid="CIT0007">7</xref>,<xref rid="CIT0012">12</xref>,<xref rid="CIT0013">13</xref>]</td></tr><tr><td align="left">Lopinavir</td><td align="left">Protease inhibitor</td><td align="center">[<xref rid="CIT0007">7</xref>,<xref rid="CIT0012">12</xref>,<xref rid="CIT0013">13</xref>]</td></tr><tr><td align="left">Camostat</td><td align="left">Fusion inhibitor</td><td align="center">[<xref rid="CIT0014">14</xref>]</td></tr><tr><td align="left">Heptad repeat 2 peptide (HR2P)</td><td align="left">Fusion inhibitor</td><td align="center">[<xref rid="CIT0015">15</xref>]</td></tr><tr><td align="left">Cyclosporine</td><td align="left">Affects the function of many cyclophilins that act as chaperones and facilitate protein folding</td><td align="center">[<xref rid="CIT0016">16</xref>,<xref rid="CIT0017">17</xref>]</td></tr><tr><td align="left">Nitazoxanide</td><td align="left">Broad-spectrum antiviral agent</td><td align="center">[<xref rid="CIT0018">18</xref>,<xref rid="CIT0019">19</xref>]</td></tr><tr><td align="left">Teicoplanin</td><td align="left">Inhibits cathepsin L in the late endosome/lysosome and block the entry of MERS-CoV</td><td align="center">[<xref rid="CIT0018">18</xref>,<xref rid="CIT0019">19</xref>]</td></tr><tr><td align="left">Mycophenolate</td><td align="left">Direct and indirect antiviral activity by modulation of IFN response</td><td align="center">[<xref rid="CIT0020">20</xref>]</td></tr></tbody></table></table-wrap></p><p>Interferon is antiviral type I IFN system, a major part of the innate immune response [<xref rid="CIT0007">7</xref>,<xref rid="CIT0008">8</xref>]. <italic>In vitro</italic> studies showed that IFN-β has an IC<sub>50</sub> of 1.37 U/mL and that IFN-β has anti-MERS-CoV activity of 16-, 41-, 83-, and 117-fold higher than IFN-α2b, IFN-γ, IFN-universal type 1 and IFN-α2a, respectively [<xref rid="CIT0009">9</xref>]. <italic>In vitro</italic> studies showed that IFN-β has a lower IC50 for MERS-CoV compared to IFN-a2b [<xref rid="CIT0009">9</xref>].</p><p>Ribavirin is a nucleoside analog that is activated by host kinases to a nucleotide [<xref rid="CIT0007">7</xref>,<xref rid="CIT0010">10</xref>,<xref rid="CIT0011">11</xref>]. It was shown that <italic>in vitro</italic> doses of ribavirin required to inhibit MERS-CoV replications are too high to be achieved <italic>in vivo</italic> [<xref rid="CIT0007">7</xref>,<xref rid="CIT0010">10</xref>]. Nelfinavir and lopinavir inhibit MERS-CoV <italic>in vitro</italic> [<xref rid="CIT0007">7</xref>,<xref rid="CIT0012">12</xref>]. The mean 50% effective concentration (EC50) of lopinavir using Vero E6 and Huh7 cells was 8.0 μM [<xref rid="CIT0013">13</xref>].</p><p>Camostat and the heptad repeat 2 peptide (HR2P) are two MERS-CoV fusion inhibitors that were tested <italic>in vitro</italic> [<xref rid="CIT0014">14</xref>,<xref rid="CIT0015">15</xref>]. The fusion inhibitor, camostat, inhibited viral entry into human bronchial submucosal gland-derived Calu-3 cells but not the immature lung tissue [<xref rid="CIT0014">14</xref>]. The second fusion inhibitor, HR2P, inhibits MERS-CoV replication and the spike protein-mediated cell-cell fusion [<xref rid="CIT0015">15</xref>].</p><p>Cyclosporin affects the function of many cyclophilins that act as chaperones and facilitate protein folding [<xref rid="CIT0016">16</xref>,<xref rid="CIT0017">17</xref>]. <italic>In vitro</italic>, cyclosporine inhibited MERS-CoV replication [<xref rid="CIT0016">16</xref>,<xref rid="CIT0017">17</xref>]. Nitazoxanide, a broad-spectrum antiviral agent, and teicoplanin, an inhibitor of cathepsin L in the late endosome/lysosome and blocker of the entry of MERS-CoV, also showed inhibitory effect of MERS-CoV <italic>in vitro</italic> [<xref rid="CIT0018">18</xref>,<xref rid="CIT0019">19</xref>].</p></sec><sec id="S0004"><label>4.</label><title>Animal model and the use of anti-MERS-CoV agents</title><p>There are few studies evaluating various agents as therapy for MERS-CoV in animal models (<xref rid="T0002">Table 2</xref>) [<xref rid="CIT0012">12</xref>,<xref rid="CIT0021">21</xref>–<xref rid="CIT0024">24</xref>]. In the rhesus macaques model, interferon-α2b-ribavirin combination decreased viral replication within 8 h of MERS-CoV infection [<xref rid="CIT0025">25</xref>]. In a primate model, the mortality rate at 36 h post-inoculation was reduced from 67% in untreated to 0–33% in animals treated with a combination of interferon-β1b and either lopinavir or ritonavir [<xref rid="CIT0012">12</xref>]. Intranasal use of an HR2P analog with improved pharmaceutical property, HR2P-M2, was protective in mice model [<xref rid="CIT0021">21</xref>]. In an animal model using MERS-CoV infected mice, the use of high titer MERS immune camel serum was effective in reducing lung injury and acceleration of virus clearance [<xref rid="CIT0022">22</xref>]. Mycophenolate has a direct and indirect antiviral activity by modulation of IFN response [<xref rid="CIT0020">20</xref>]. The use of mycophenolate in the common marmoset animal model resulted in higher mortality than untreated animals [<xref rid="CIT0012">12</xref>]. A monoclonal antibody designated as m336 is an antibody derived from a large phage-displayed antibody library from B cells of healthy donors [<xref rid="CIT0026">26</xref>]. The use of this m336 in mice showed promising results as a therapeutic and a prophylactic agent [<xref rid="CIT0023">23</xref>].
<table-wrap id="T0002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1080/14787210.2017.1271712-T0002</object-id><label>Table 2.</label><caption><p>A summary of animal model of therapeutic agents against MERS-CoV infection.</p></caption><pmc-comment>OASIS TABLE HERE</pmc-comment><table frame="hsides" rules="groups"><colgroup><col width="1*" align="left"></col><col width="1*" align="left"></col><col width="1*" align="left"></col><col width="1*" align="left"></col><col width="1*" align="center"></col></colgroup><thead><tr><th align="left">Number</th><th align="center">Animal model</th><th align="center">Treatment</th><th align="center">Outcome</th><th align="center">Reference</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Primate</td><td align="left">Interferon-β1b and either lopinavir or ritonavir</td><td align="left">Mortality rate at 36 h post-inoculation was reduced from 67% in untreated to 0–33% in animals treated with a combination of Interferon-β1b and either lopinavir or ritonavir</td><td align="center">[<xref rid="CIT0012">12</xref>]</td></tr><tr><td align="left">2</td><td align="left">Mice</td><td align="left">HR2P analog</td><td align="left">>1000-fold reduction of viral titers in lung</td><td align="center">[<xref rid="CIT0021">21</xref>]</td></tr><tr><td align="left">3</td><td align="left">Mice</td><td align="left">High-titer MERS immune camel serum</td><td align="left">Increase the kinetics of MERS-CoV clearance and decrease severity of pathological changes</td><td align="center">[<xref rid="CIT0022">22</xref>]</td></tr><tr><td align="left">4</td><td align="left">Primate</td><td align="left">Mycophenolate</td><td align="left">Mortality rate was 67% (untreated and MMF treated) at 36 h post inoculation vs. 0–33% (lopinavir/ritonavir-treated and interferon-β1b-treated)</td><td align="center">[<xref rid="CIT0012">12</xref>]</td></tr><tr><td align="left">5</td><td align="left">Transgenic mice</td><td align="left">Germline-like neutralizing human monoclonal antibody</td><td align="left">Treated mice prior to or post lethal MERS-CoV challenge were fully protected</td><td align="center">[<xref rid="CIT0023">23</xref>]</td></tr><tr><td align="left">6</td><td align="left">Mouse model</td><td align="left">Humanized monoclonal antibody, hms-1, against RBD</td><td align="left">Single-dose completely protected transgenic mice from lethal MERS-CoV</td><td align="center">[<xref rid="CIT0024">24</xref>]</td></tr></tbody></table></table-wrap></p><p>Currently, there is no animal model that completely reflects the course of MERS-CoV disease in humans and thus the data obtained from these animal models are to be interpreted cautiously. And animal models utilize therapy shortly after infection.</p></sec><sec id="S0005"><label>5.</label><title>Clinical use of combination therapy of ribavirin-interferon in MERS-CoV patients</title><p>Based on analysis of SARS data, interferon-ribavirin combination was suggested as a possible therapeutic option for the treatment of MERS-CoV infections [<xref rid="CIT0005">5</xref>]. Limited data are available regarding the clinical efficacy of antiviral agents [<xref rid="CIT0027">27</xref>–<xref rid="CIT0036">36</xref>] (<xref rid="T0003">Table 3</xref>). The first use of the combination of ribavirin-interferon therapy was in five patients with MERS infection [<xref rid="CIT0027">27</xref>]. The therapy was started late in the course of the disease with a median time from admission to therapy of 19 days [<xref rid="CIT0027">27</xref>]. Of the included 5 patients, none responded to therapy [<xref rid="CIT0027">27</xref>].<table-wrap id="T0003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1080/14787210.2017.1271712-T0003</object-id><label>Table 3.</label><caption><p>Clinical experience with antiviral therapy for MERS-CoV infection.</p></caption><pmc-comment>OASIS TABLE HERE</pmc-comment><table frame="hsides" rules="groups"><colgroup><col width="1*" align="left"></col><col width="1*" align="left"></col><col width="1*" align="left"></col><col width="1*" align="left"></col><col width="1*" align="char" char="."></col><col width="1*" align="left"></col><col width="1*" align="center"></col><col width="1*" align="center"></col></colgroup><thead><tr><th align="left">Number</th><th align="center">Study type</th><th align="center">Treatment</th><th align="center">Time to initiation of therapy</th><th align="center" char=".">Treatment group, <italic>n</italic>/<italic>N</italic> (% survival)</th><th align="center">Control group</th><th align="center">Level of evidence</th><th align="center">Reference</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Case series</td><td align="left">Ribavirin and interferon-alfa 2b</td><td align="left">19 days post-admission</td><td align="char" char=".">0/5 (0)</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0027">27</xref>]</td></tr><tr><td align="left">2</td><td align="left">Retrospective cohort study</td><td align="left">Ribavirin and interferon-alfa 2a</td><td align="left">3 days of onset</td><td align="center" char=".">14/20 (70 at 14 days); 6/20 (30 at 28 days)</td><td align="left">24; survival at 14 days 29% and 17% at 28 days</td><td align="center">4</td><td align="center">[<xref rid="CIT0028">28</xref>]</td></tr><tr><td align="left">3</td><td align="left">Case series</td><td align="left">Ribavirin and interferon-alfa 2a</td><td align="left">6 days of onset</td><td align="char" char=".">11/11 (100)</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0029">29</xref>]</td></tr><tr><td align="left">4</td><td align="left">Case series</td><td align="left">Ribavirin and interferon-alfa 2a</td><td align="left">1 day following diagnosis</td><td align="char" char=".">11/13 (85)</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0030">30</xref>]</td></tr><tr><td align="left">5</td><td align="left">Case series</td><td align="left">Ribavirin and interferon-b1a</td><td align="left">1 day following diagnosis</td><td align="char" char=".">7/11 (64)</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0030">30</xref>]</td></tr><tr><td align="left">6</td><td align="left">Case series</td><td align="left">Interferon beta</td><td align="left">Not indicated</td><td align="char" char=".">18/23 (78.3)</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0031">31</xref>]</td></tr><tr><td align="left">7</td><td align="left">Case series</td><td align="left">Interferon alpha</td><td align="left">Not indicated</td><td align="char" char=".">6/8 (75)</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0031">31</xref>]</td></tr><tr><td align="left">8</td><td align="left">Case series</td><td align="left">Ribavirin</td><td align="left">Not indicated</td><td align="char" char=".">13/19 (68.4)</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0031">31</xref>]</td></tr><tr><td align="left">9</td><td align="left">Case series</td><td align="left">Mycophenolate mofetil</td><td align="left">Not indicated</td><td align="char" char=".">8/8 (100)</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0031">31</xref>]</td></tr><tr><td align="left">10</td><td align="left">Case report</td><td align="left">Lopinavir/ritonavir, ribavirin, and interferon-α</td><td align="left">Not indicated</td><td align="center" char=".">None</td><td align="left">4</td><td align="center">4</td><td align="center">[<xref rid="CIT0032">32</xref>]</td></tr><tr><td align="left">11</td><td align="left">Case report</td><td align="left">Pegylated interferon, ribavirin and lopinavir/ritonavir</td><td align="left">From Day 13 of illness</td><td align="center" char=".">?</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0033">33</xref>]</td></tr><tr><td align="left">12</td><td align="left">Case report</td><td align="left">Ribavirin and interferon-alfa 2a</td><td align="left">Day 1 of admission</td><td align="center" char=".">Survived</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0034">34</xref>]</td></tr><tr><td align="left">13</td><td align="left">Case report</td><td align="left">Ribavirin and interferon-alfa 2a</td><td align="left">Day 12 from onset</td><td align="center" char=".">Died</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0035">35</xref>]</td></tr><tr><td align="left">14</td><td align="left">Case series</td><td align="left">Ribavirin and interferon-alfa 2b</td><td align="left">1–2 days in survivals and 12–19 days in those who died</td><td align="char" char=".">3/6 (50)</td><td align="left">None</td><td align="center">4</td><td align="center">[<xref rid="CIT0036">36</xref>]</td></tr></tbody></table></table-wrap></p><p>In a subsequent retrospective cohort study, 20 MERS patients received ribavirin-interferon compared to 24 patients who did not [<xref rid="CIT0028">28</xref>]. The 14-day survival rate was better in those who received the combination therapy (70% vs. 29%, <italic>p</italic> = 0.004); however, the 28-day survival rate was not statistically different (30% vs. 17%) (<xref rid="T0001">Table 1</xref>) [<xref rid="CIT0028">28</xref>]. In another case series, 11 MERS patients had ribavirin and peg-interferon α-2a [<xref rid="CIT0029">29</xref>].</p><p>Ribavirin-IFN-α2a was compared to ribavirin-IFN-β1a in a study of 13 and 11 patients, respectively [<xref rid="CIT0030">30</xref>]. The mortality rate was not statistically different between the two groups (85% vs. 64%) [<xref rid="CIT0030">30</xref>]. In a large cohort study of 51 patients, various combinations of interferon and ribavirin were used with different outcomes (<xref rid="T0003">Table 3</xref>) [<xref rid="CIT0031">31</xref>]. In a case series of 6 patients, 3 patients received ribavirin and interferon-alfa 2b within 1–2 days of admission and they survived compared to the other 3 patients who died as they received the therapy 12–19 days after admission [<xref rid="CIT0036">36</xref>]. Another study evaluated the use of interferon beta, interferon alpha, or ribavirin and showed survival rates of 18/23 (78.3%), 6/8 (75%), and 13/19 (68.4%), respectively (<xref rid="T0003">Table 3</xref>) [<xref rid="CIT0031">31</xref>]. The combination therapy was also used in other case reports (<xref rid="T0003">Table 3</xref>) [<xref rid="CIT0033">33</xref>,<xref rid="CIT0034">34</xref>].</p><p>The role of the combination of ribavirin and IFN was also tried as a treatment and a prophylaxis [<xref rid="CIT0034">34</xref>]. The current studies of the use of ribavirin and IFN combination therapy for MERS-CoV infection rely on small number of patients but there is a trend for improvement. Thus, it was suggested that the combination of type 1 interferon and ribavirin could be used [<xref rid="CIT0037">37</xref>]. Due to the inhomogeneous nature of available studies and the limited data that are available, a precise recommendation on therapy of MERS could not be established.</p></sec><sec id="S0006"><label>6.</label><title>Other combinations (lopinavir/ritonavir, ribavirin, and interferon)</title><p>The combination of lopinavir/ritonavir, ribavirin and interferon-alpha was used in one case [<xref rid="CIT0032">32</xref>]. One patient received pegylated interferon, ribavirin, and lopinavir/ritonavir from day 13 of illness and the patient had continued MERS-CoV in the respiratory tract secretions until the fourth week of illness [<xref rid="CIT0033">33</xref>]. However, viremia was detected for only 2 days after initiation of triple therapy [<xref rid="CIT0033">33</xref>]. In a case series, eight patients received mycophenolate mofetil and all survived [<xref rid="CIT0031">31</xref>].</p></sec><sec id="S0007"><label>7.</label><title>Neutralizing antibodies</title><p>In the SARS epidemic, passive immunotherapy with neutralizing antibodies was considered as a therapeutic approach. There are multiple antibodies against MERS-CoV [<xref rid="CIT0038">38</xref>–<xref rid="CIT0048">48</xref>] (<xref rid="T0004">Table 4</xref>). In the MERS-CoV infection, the production of large quantities of MERS-CoV neutralizing human polyclonal antibodies was possible using gamma-irradiated whole-killed virion vaccine or a spike protein nanoparticle vaccine in a bovine model [<xref rid="CIT0049">49</xref>]. Utilizing one dose of these antibodies prevented infection in mice [<xref rid="CIT0049">49</xref>]. These antibodies were effective when given 12 h before or 24 and 48 h after MERS-CoV infection [<xref rid="CIT0049">49</xref>].
<table-wrap id="T0004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1080/14787210.2017.1271712-T0004</object-id><label>Table 4.</label><caption><p>A summary of generated anti-MERS-CoV antibodies.</p></caption><pmc-comment>OASIS TABLE HERE</pmc-comment><table frame="hsides" rules="groups"><colgroup><col width="1*" align="left"></col><col width="1*" align="left"></col><col width="1*" align="center"></col></colgroup><thead><tr><th align="left">Number</th><th align="left">Antibody</th><th align="center">Reference</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Anti-CD26 monoclonal antibody</td><td align="center">[<xref rid="CIT0038">38</xref>]</td></tr><tr><td align="left">2</td><td align="left">Anti–MERS-CoV spike protein antibodies</td><td align="center">[<xref rid="CIT0039">39</xref>]</td></tr><tr><td align="left">3</td><td align="left">Recombinant receptor-binding domain of S spike</td><td align="center">[<xref rid="CIT0040">40</xref>]</td></tr><tr><td align="left">4</td><td align="left">Receptor-binding domain in S spike protein</td><td align="center">[<xref rid="CIT0041">41</xref>]</td></tr><tr><td align="left">5</td><td align="left">Receptor-binding domain in S spike protein</td><td align="center">[<xref rid="CIT0042">42</xref>]</td></tr><tr><td align="left">6</td><td align="left">Receptor-binding domain in S spike protein</td><td align="center">[<xref rid="CIT0043">43</xref>]</td></tr><tr><td align="left">7</td><td align="left">Receptor-binding domain in S spike protein</td><td align="center">[<xref rid="CIT0044">44</xref>]</td></tr><tr><td align="left">8</td><td align="left">Receptor-binding domain in S spike protein</td><td align="center">[<xref rid="CIT0045">45</xref>]</td></tr><tr><td align="left">9</td><td align="left">S spike protein</td><td align="center">[<xref rid="CIT0046">46</xref>]</td></tr><tr><td align="left">10</td><td align="left">Human neutralizing antibodies</td><td align="center">[<xref rid="CIT0044">44</xref>]</td></tr><tr><td align="left">11</td><td align="left">Human monoclonal antibodies against CD26/DPP4-binding domain</td><td align="center">[<xref rid="CIT0045">45</xref>]</td></tr><tr><td align="left">12</td><td align="left">Human RBD-specific neutralizing monoclonal antibodies</td><td align="center">[<xref rid="CIT0043">43</xref>]</td></tr><tr><td align="left">13</td><td align="left">A human anti-MERS monoclonal antibody 3B11-N</td><td align="center">[<xref rid="CIT0047">47</xref>]</td></tr><tr><td align="left">14</td><td align="left">S spike protein</td><td align="center">[<xref rid="CIT0048">48</xref>]</td></tr></tbody></table></table-wrap></p><p>Corti et al. isolated a potent MERS-CoV-neutralizing antibody (LCA60) from memory B cells of an infected individual. The LCA60 antibodies bind to a site on the spike protein and neutralize MERS-CoV infection [<xref rid="CIT0048">48</xref>]. These LCA60 antibodies were used successfully in mice model [<xref rid="CIT0048">48</xref>]. Similarly, utilizing a humanized mouse model of MERS-CoV infection, antibodies against the spike protein were efficacious as prophylaxis [<xref rid="CIT0039">39</xref>]. Antibodies obtained from the sera of MERS immune camels were supportive of the clearance of the virus, and reduction of the severity of the disease in MERS-CoV-infected mice [<xref rid="CIT0022">22</xref>]. However, the purification and safety of these antibodies in humans has not been established yet.</p><p>The cellular dipeptidyl peptidase IV (DDP IV; known as CD26 or adenosine deaminase (ADA)-complexing protein-2) is an important receptor that mediates MERS-CoV infection through the viral spike (S) protein [<xref rid="CIT0046">46</xref>,<xref rid="CIT0050">50</xref>]. The MERS-CoV receptor binding domain (RBD), present on the surface spike protein (S), binds to the host cells receptor DPP IV [<xref rid="CIT0046">46</xref>,<xref rid="CIT0050">50</xref>,<xref rid="CIT0051">51</xref>]. In humans, DPP IV is present mainly on the lower respiratory tract area such as the bronchial epithelial and alveolar cells [<xref rid="CIT0052">52</xref>,<xref rid="CIT0053">53</xref>]. Although DDP IV is important for the viral entry into host cells, the use of DPP IV inhibitors, sitagliptin, vildagliptin, and saxagliptin, does not block the infection of MERS-CoV [<xref rid="CIT0050">50</xref>]. <italic>In vitro</italic> use of monoclonal antibodies (MERS-4) exhibited IC50 of 0.056 µg/mL [<xref rid="CIT0043">43</xref>]. Other possible human mAb (m336, m337, and m338) neutralize pseudovirus and live virus [<xref rid="CIT0045">45</xref>]. In rhesus model of MERS-CoV infection, a human monoclonal antibody, 3B11-N, against MERS-CoV was effective in reducing the pathology of MERS-CoV [<xref rid="CIT0047">47</xref>]. The use of polyclonal antibody (pAb) against CD26 inhibits MERS-CoV infection <italic>in vitro</italic> [<xref rid="CIT0050">50</xref>]. Humanized anti-CD26 monoclonal antibodies (MAb) such as MAb YS110 and 2F9 significantly inhibit MERS-COV infection <italic>in vitro</italic> [<xref rid="CIT0038">38</xref>]. Polyclonal antibodies against the MERS-COV S1 domain neutralize the virus infection [<xref rid="CIT0046">46</xref>]. Many other MERS-CoV antibodies are being developed and tested [<xref rid="CIT0038">38</xref>].</p></sec><sec id="S0008"><label>8.</label><title>Convalescent plasma</title><p>In the SARS epidemic, convalescent plasma was thought to improve the outcome of SARS patients [<xref rid="CIT0005">5</xref>]. Previous studies suggest that convalescent plasma may be used for patients with SARS and severe influenza and may result in decreased viral load and a lower mortality rate [<xref rid="CIT0054">54</xref>–<xref rid="CIT0057">57</xref>]. However, most of the studies were of low or very low quality, lacked control groups, and had risk of bias [<xref rid="CIT0058">58</xref>]. Two patients with MERS-CoV infection received intravenous immunoglobulin in an attempt to treat the infection, one patient was in Saudi Arabia [<xref rid="CIT0059">59</xref>] and the other was in the USA [<xref rid="CIT0060">60</xref>]. A protocol for the use of convalescent plasma as a therapeutic option for MERS was suggested [<xref rid="CIT0061">61</xref>]. Plasma donors were identified as those with anti-MERS-CoV indirect immunofluorescence assay (IFA) antibodies (titer of ≥1:160) with no evidence of active MERS-CoV infection [<xref rid="CIT0061">61</xref>]. In nine confirmed survivors of MERS-CoV infection, 55%, 33%, and 22% of them had positive MERS antibodies by IFA at 3, 10, and 18 months, respectively [<xref rid="CIT0062">62</xref>]. The two patients who had long lasting antibodies had severe disease; however, the titer of the IFA antibodies was not measured in the study [<xref rid="CIT0062">62</xref>]. In a larger study, MERS-CoV neutralizing antibodies were produced at low levels and were short-lived [<xref rid="CIT0063">63</xref>]. Further studies of the kinetics of the MERS-CoV antibodies showed that all surviving patients and 50% of fatal cases produced IgG and neutralizing antibodies [<xref rid="CIT0064">64</xref>]. The presence of antibodies did not lead to the elimination of virus from the lower respiratory tract [<xref rid="CIT0064">64</xref>]. In a study of 12 patients from South Korea, nine patients had PRNT50 titers >1:320 by day 21 and two had titers >1:320 by day 28 [<xref rid="CIT0065">65</xref>]. In a study of 443 samples, 12 (2.7%) had reactive ELISA results, and 9 of those had reactive indirect fluorescent antibody and microneutralization assay titers [<xref rid="CIT0066">66</xref>]. Thus, the use of convalescent plasma for the treatment of MERS-CoV in a clinical trial may be challenging due to a small pool of potential donors with sufficient antibody titers [<xref rid="CIT0066">66</xref>].</p></sec><sec id="S0009"><label>9.</label><title>Glucocorticoid</title><p>Based on SARS experience, some authors suggested that steroid therapy might be beneficial for severe MERS-COV infection [<xref rid="CIT0067">67</xref>]. Corticosteroid use for patients with SARS showed that early use of corticosteroids significantly increased viral load, and 20.7-fold increase in risk of ICU admission and mortality [<xref rid="CIT0068">68</xref>]. In another study of 16 non-ICU patients, the median time for SARS-CoV to become undetectable in plasma was 12 days compared to 8 days in patients who did and did not receive early corticosteroid therapy [<xref rid="CIT0069">69</xref>].</p><p>Corticosteroids were used as adjunct therapy for many patients with MERS-CoV [<xref rid="CIT0027">27</xref>,<xref rid="CIT0070">70</xref>]. In a study of 13 patients with MERS-CoV infection, one patient received steroid and intravenous immunoglobulin for thrombocytopenia [<xref rid="CIT0059">59</xref>]. Initial study of five patients, three patients received a combination of interferon and ribavirin in addition to adjunct steroid on day 0–21 and all died during hospitalization [<xref rid="CIT0027">27</xref>]. However, steroids were not evaluated systematically as therapy for MERS patients.</p></sec><sec id="S0010"><label>10.</label><title>Other therapeutic drugs</title><p>The host protease, furin, is an important factor to break down the S1-S2 region of the MERS-CoV [<xref rid="CIT0071">71</xref>]. <italic>In vivo</italic> studies showed activity of multiple agents against MERS-CoV and include: chloroquine, chlorpromazine, cyclosporine, and mycophenolic acid [<xref rid="CIT0007">7</xref>,<xref rid="CIT0072">72</xref>]. In addition, the US FDA approved repurposed agents with broad antiviral activity including <italic>in vitro</italic> activity against MERS-CoV [<xref rid="CIT0073">73</xref>]. These agents include the polymerase inhibitor BCX4430 and the helicase inhibitor SSYA10-001, spike binding (immunoadhesin (DPP4-Fc)) [<xref rid="CIT0073">73</xref>]. There are many other agents currently in preclinical investigation such as: fluspirilene, thiothixene, fluphenazine hydrochloride, promethazine hydrochloride, astemizole and chlorphenoxamine hydrochloride [<xref rid="CIT0072">72</xref>].</p></sec><sec id="S0011"><label>11.</label><title>Expert commentary</title><p>The emergence and continued cases of MERS-CoV infection require the availability of MERS therapy. There is an urgent need for the development of standardized animal models and the establishment of standardized clinical therapeutic protocols. The current clinical studies are limited to case reports and case series with no control arm. The quality of evidence these studies offer is too low to make a conclusion. It is difficult to draw conclusion in the face of these limited studies. The most used combination of therapy was interferon and ribavirin as developed initially in 2013. The development of novel therapeutic agents or the repurposing old therapeutic agents against MERS-CoV are needed as alternative pathways for testing and clinical trials. It was thought that convalescent sera may provide an exciting alternative as a therapeutic agent; the present data does not support the wide adaptation of this therapy. The current MERS therapy relies on supportive care and providing circulatory and ventilation support.</p></sec><sec id="S0012"><label>12.</label><title>Five-year view</title><p>It is expected that the development and the use of repurposed drugs would allow the development of therapeutic agents for MERS-CoV. The best location to provide a randomized controlled trail was thought to be the intensive care units for the use of convalescent sera; the presence of milder disease may necessitate the development of therapeutic protocols for patients with severe and those with milder disease. Monoclonal and polyclonal antibodies may offer further therapeutic options for the disease in humans. Since the prospect for a randomized clinical trial is low due to the sporadic nature of the disease outside hospital outbreaks, it is prudent to have well-conducted prospective clinical studies. The proteins involved in MERS-CoV entry and replication are attractive targets for the development of antiviral therapeutics. Clinical studies utilizing anti-MERS-CoV antibodies as therapeutic options would add to the prospect to develop therapeutic agents for this syndrome. Although many drugs appear to be effective <italic>in vitro</italic>, a consideration of their availability, pharmacokinetic/pharmacodynamic properties, and side effects should be taken into consideration. Of medications with an attractive use, lopinavir, interferon, and mycophenolate are among these agents. Accelerated and preferably randomized controlled trails should be conducted. Neutralizing antibodies are also promising and the use of these agents in humans. Targeting the DDP4 receptor may be of particular importance; however, it is important to keep in mind that the development of any mutation in the binding sites may limit the use of these agents [<xref rid="CIT0074">74</xref>]. Few monoclonal antibodies showed protective efficacy as a prophylaxis in animal models [<xref rid="CIT0039">39</xref>,<xref rid="CIT0048">48</xref>]. The development and testing of monoclonal antibodies are associated with high costs and lack of an undefined population for their use [<xref rid="CIT0075">75</xref>]. These monoclonal bodies had not been used in phase 1 clinical trials and that further development of these agents require time and cost.</p></sec><sec id="S0013"><title>Key issues</title><p><list list-type="bullet"><list-item><p>MERS-CoV emerged in 2012 and has caused multiple hospital outbreaks.</p></list-item><list-item><p>Currently, there are no licensed therapeutic agents for MERS-CoV infection.</p></list-item><list-item><p>Multiple monoclonal and polyclonal antibodies were developed and may offer therapeutic options.</p></list-item><list-item><p>Repurposing old drugs against MERS-CoV is an interesting strategy that deserves further development and use in clinical settings.</p></list-item><list-item><p>Current clinical data are limited to case reports and case series in the use of combination antiviral medications such as ribavirin and interferon.</p></list-item><list-item><p>The combination of ribavirin and interferon may offer a survival advantage at 14 days but not at 28 days.</p></list-item><list-item><p>Animal models are promising in further delineating the disease and the therapeutic options.</p></list-item><list-item><p>Further studies should include <italic>in vitro</italic> mechanism studies, enhancing animal models of MERS-CoV infection, clinical trials, and evaluation of combination therapy.</p></list-item></list></p></sec></body><back><sec id="S0014"><title>Declaration of interest</title><p>The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</p></sec><ref-list><title>References</title><p>Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.</p><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Tawfiq</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Memish</surname><given-names>ZA.</given-names></name></person-group><article-title>Managing MERS-CoV in the healthcare setting</article-title>. <source>Hosp Pr</source>. <year>2015</year>;<volume>43</volume>:<fpage>158</fpage>–<lpage>163</lpage>.</mixed-citation><note><p><bold>• A review of MERS-CoV in healthcare setting.</bold></p></note></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assiri</surname><given-names>A</given-names></name>, <name name-style="western"><surname>McGeer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Perl</surname><given-names>TM</given-names></name>, et al</person-group><article-title>Hospital outbreak of Middle East respiratory syndrome coronavirus</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>369</volume>:<fpage>407</fpage>–<lpage>416</lpage>.<pub-id pub-id-type="pmid">23782161</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Tawfiq</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Perl</surname><given-names>TM</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus in healthcare settings</article-title>. <source>Curr Opin Infect Dis</source>. <year>2015</year>;<volume>28</volume>:<fpage>392</fpage>–<lpage>396</lpage>.<pub-id pub-id-type="pmid">26103552</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Middle East respiratory syndrome coronavirus (MERS-CoV)</article-title><year>n d.</year><comment>Available from:</comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/emergencies/mers-cov/en/">http://www.who.int/emergencies/mers-cov/en/</ext-link></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Momattin</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Mohammed</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zumla</surname><given-names>A</given-names></name>, et al</person-group><article-title>Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)–possible lessons from a systematic review of SARS-CoV therapy</article-title>. <source>Int J Infect Dis</source>. <year>2013</year>;<volume>17</volume>:<fpage>e792</fpage>–<lpage>e798</lpage>.<pub-id pub-id-type="pmid">23993766</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>Oxford Centre for Evidence-based Medicine</collab></person-group><article-title>Oxford centre for evidence-based medicine - levels of evidence (March 2009) – CEBM</article-title>. <year>2009</year><date-in-citation>[cited 2016 <month>9</month><day>21</day>]</date-in-citation><comment>Available from:</comment><ext-link ext-link-type="uri" xlink:href="http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009">http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009</ext-link></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>KH</given-names></name>, <name name-style="western"><surname>Kao</surname><given-names>RY</given-names></name>, et al</person-group><article-title>Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus</article-title>. <source>J Infect</source>. <year>2013</year>;<volume>67</volume>:<fpage>606</fpage>–<lpage>616</lpage>.<pub-id pub-id-type="pmid">24096239</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Randall</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Goodbourn</surname><given-names>S</given-names></name></person-group><article-title>Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures</article-title>. <source>J Gen Virol</source>. <year>2008</year>;<volume>89</volume>:<fpage>1</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">18089727</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hart</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Dyall</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Postnikova</surname><given-names>E</given-names></name>, et al</person-group><article-title>Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays</article-title>. <source>J Gen Virol</source>. <year>2014</year>;<volume>95</volume>:<fpage>571</fpage>–<lpage>577</lpage>.<pub-id pub-id-type="pmid">24323636</pub-id></mixed-citation><note><p><bold>• A study of the inhibitors of MERS-CoV.</bold></p></note></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falzarano</surname><given-names>D</given-names></name>, <name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Martellaro</surname><given-names>C</given-names></name>, et al</person-group><article-title>Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin</article-title>. <source>Sci Rep</source>. <year>2013</year>;<volume>3</volume>:<fpage>1686</fpage>.<pub-id pub-id-type="pmid">23594967</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adedeji</surname><given-names>AO</given-names></name>, <name name-style="western"><surname>Sarafianos</surname><given-names>SG</given-names></name></person-group><article-title>Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection</article-title>. <source>Future Med Chem</source>. <year>2013</year>;<volume>5</volume>:<fpage>2119</fpage>–<lpage>2122</lpage>.<pub-id pub-id-type="pmid">24261888</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>JF-W</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yeung</surname><given-names>M-L</given-names></name>, et al</person-group><article-title>Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset</article-title>. <source>J Infect Dis</source>. <year>2015</year>;<volume>212</volume>:<fpage>1904</fpage>–<lpage>1913</lpage>.<pub-id pub-id-type="pmid">26198719</pub-id></mixed-citation><note><p><bold>• A primate model of MERS-CoV infection.</bold></p></note></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Wilde</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Jochmans</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Posthuma</surname><given-names>CC</given-names></name>, et al</person-group><article-title>Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>:<fpage>4875</fpage>–<lpage>4884</lpage>.<pub-id pub-id-type="pmid">24841269</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirato</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kawase</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Matsuyama</surname><given-names>S</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus (MERS-CoV) infection mediated by the transmembrane serine protease TMPRSS2</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>:<fpage>12552</fpage>–<lpage>12561</lpage>.<pub-id pub-id-type="pmid">24027332</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name>, et al</person-group><article-title>Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor</article-title>. <source>Nat Commun</source>. <year>2014</year>;<volume>5</volume>:<fpage>3067</fpage>.<pub-id pub-id-type="pmid">24473083</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Wilde</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Raj</surname><given-names>VS</given-names></name>, <name name-style="western"><surname>Oudshoorn</surname><given-names>D</given-names></name>, et al</person-group><article-title>MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment</article-title>. <source>J Gen Virol</source>. <year>2013</year>;<volume>94</volume>:<fpage>1749</fpage>–<lpage>1760</lpage>.<pub-id pub-id-type="pmid">23620378</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Wilde</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Zevenhoven-Dobbe</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>van der Meer</surname><given-names>Y</given-names></name>, et al</person-group><article-title>Cyclosporin A inhibits the replication of diverse coronaviruses</article-title>. <source>J Gen Virol</source>. <year>2011</year>;<volume>92</volume>:<fpage>2542</fpage>–<lpage>2548</lpage>.<pub-id pub-id-type="pmid">21752960</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossignol</surname><given-names>J-F</given-names></name></person-group><article-title>Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus</article-title>. <source>J Infect Public Health</source>. <year>2016</year>;<volume>9</volume>:<fpage>227</fpage>–<lpage>230</lpage>.<pub-id pub-id-type="pmid">27095301</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, et al</person-group><article-title>Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)</article-title>. <source>J Biol Chem</source>. <year>2016</year>;<volume>291</volume>:<fpage>9218</fpage>–<lpage>9232</lpage>.<pub-id pub-id-type="pmid">26953343</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>De Ruiter</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Metselaar</surname><given-names>HJ</given-names></name>, et al</person-group><article-title>Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C virus infection in vitro and in vivo</article-title>. <source>Hepatology</source>. <year>2012</year>;<volume>55</volume>:<fpage>1673</fpage>–<lpage>1683</lpage>.<pub-id pub-id-type="pmid">22213147</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>S</given-names></name>, et al</person-group><article-title>Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection</article-title>. <source>J Infect Dis</source>. <year>2015</year>;<volume>212</volume>:<fpage>1894</fpage>–<lpage>1903</lpage>.<pub-id pub-id-type="pmid">26164863</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Perera</surname><given-names>RAPM</given-names></name>, <name name-style="western"><surname>Kayali</surname><given-names>G</given-names></name>, et al</person-group><article-title>Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection</article-title>. <source>J Virol</source>. <year>2015</year>;<volume>89</volume>:<fpage>6117</fpage>–<lpage>6120</lpage>.<pub-id pub-id-type="pmid">25787284</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Ying</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>X</given-names></name>, et al</person-group><article-title>Passive transfer of A Germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal Middle East respiratory syndrome coronavirus infection</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>31629</fpage>.<pub-id pub-id-type="pmid">27538452</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>H</given-names></name>, et al</person-group><article-title>Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection</article-title>. <source>Antiviral Res</source>. <year>2016</year>;<volume>132</volume>:<fpage>141</fpage>–<lpage>148</lpage>.<pub-id pub-id-type="pmid">27312105</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falzarano</surname><given-names>D</given-names></name>, <name name-style="western"><surname>de Wit</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Rasmussen</surname><given-names>AL</given-names></name>, et al</person-group><article-title>Treatment with interferon-alpha 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques</article-title>. <source>Nat Med</source>. <year>2013</year>;<volume>19</volume>:<page-range>1313–+</page-range>.</mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ying</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Prabakaran</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>L</given-names></name>, et al</person-group><article-title>Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody</article-title>. <source>Nat Commun</source>. <year>2015</year>;<volume>6</volume>:<fpage>8223</fpage>.<pub-id pub-id-type="pmid">26370782</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Tawfiq</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Momattin</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Dib</surname><given-names>J</given-names></name>, et al</person-group><article-title>Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.</article-title>. <source>Int J Infect Dis</source>. <year>2014</year>;<volume>20</volume>:<fpage>42</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">24406736</pub-id></mixed-citation><note><p><bold>•• The first study of interferon and ribavirin in MERS-CoV.</bold></p></note></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omrani</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Saad</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Baig</surname><given-names>K</given-names></name>, et al</person-group><article-title>Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study</article-title>. <source>Lancet Infect Dis</source>. <year>2014</year>;<volume>14</volume>:<fpage>1090</fpage>–<lpage>1095</lpage>.<pub-id pub-id-type="pmid">25278221</pub-id></mixed-citation><note><p><bold>•• A large cohort study of ribavirin-interferon in MERS-CoV patients.</bold></p></note></ref><ref id="CIT0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalid</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Alraddadi</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Dairi</surname><given-names>Y</given-names></name>, et al</person-group><article-title>Acute management and long-term survival among subjects with severe Middle East respiratory syndrome coronavirus pneumonia and ARDS</article-title>. <source>Respir Care</source>. <year>2016</year>;<volume>61</volume>:<fpage>340</fpage>–<lpage>348</lpage>.<pub-id pub-id-type="pmid">26701365</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shalhoub</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Farahat</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Al-Jiffri</surname><given-names>A</given-names></name>, et al</person-group><article-title>IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study</article-title>. <source>J Antimicrob Chemother</source>. <year>2015</year>;<volume>70</volume>:<fpage>2129</fpage>–<lpage>2132</lpage>.<pub-id pub-id-type="pmid">25900158</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Ghamdi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Alghamdi</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Ghandoora</surname><given-names>Y</given-names></name>, et al</person-group><article-title>Treatment outcomes for patients with Middle Eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia</article-title>. <source>BMC Infect Dis</source>. <year>2016</year>;<volume>16</volume>:<fpage>174</fpage>.<pub-id pub-id-type="pmid">27097824</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>UJ</given-names></name>, <name name-style="western"><surname>Won</surname><given-names>E-J</given-names></name>, <name name-style="western"><surname>Kee</surname><given-names>S-J</given-names></name>, et al</person-group><article-title>Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome: a case report</article-title>. <source>Antivir Ther</source>. <year>2015</year>;<volume>21</volume>:<fpage>455</fpage>–<lpage>459</lpage>.<pub-id pub-id-type="pmid">26492219</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spanakis</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Tsiodras</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name>, et al</person-group><article-title>Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen</article-title>. <source>Int J Antimicrob Agents</source>. <year>2014</year>;<volume>44</volume>:<fpage>528</fpage>–<lpage>532</lpage>.<pub-id pub-id-type="pmid">25288266</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalid</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Al Rabiah</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>B</given-names></name>, et al</person-group><article-title>Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases</article-title>. <source>Antivir Ther</source>. <year>2015</year>;<volume>20</volume>:<fpage>87</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">24831606</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>A</given-names></name>, <name name-style="western"><surname>El Masry</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Ravi</surname><given-names>M</given-names></name>, et al</person-group><article-title>Middle East respiratory syndrome coronavirus during pregnancy, Abu Dhabi, United Arab Emirates, 2013</article-title>. <source>Emerg Infect Dis</source>. <year>2016</year>;<volume>22</volume>:<fpage>515</fpage>–<lpage>517</lpage>.<pub-id pub-id-type="pmid">26890613</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalid</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Al Rabiah</surname><given-names>F</given-names></name>, et al</person-group><article-title>Middle Eastern Respiratory Syndrome corona virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia</article-title>. <source>Ann Saudi Med</source>. <year>2014</year>;<volume>34</volume>:<fpage>396</fpage>–<lpage>400</lpage>.<pub-id pub-id-type="pmid">25827696</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ki</surname><given-names>C-S</given-names></name>, <name name-style="western"><surname>Sung</surname><given-names>H</given-names></name>, et al</person-group><article-title>Guidelines for the laboratory diagnosis of Middle East respiratory syndrome coronavirus in Korea</article-title>. <source>Infect Chemother</source>. <year>2016</year>;<volume>48</volume>:<fpage>61</fpage>–<lpage>69</lpage>.<pub-id pub-id-type="pmid">27104019</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohnuma</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Hatano</surname><given-names>R</given-names></name>, et al</person-group><article-title>Inhibition of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by anti-CD26 monoclonal antibody</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>:<fpage>13892</fpage>–<lpage>13899</lpage>.<pub-id pub-id-type="pmid">24067970</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pascal</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Coleman</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Mujica</surname><given-names>AO</given-names></name>, et al</person-group><article-title>Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection</article-title>. <source>Proc Natl Acad Sci</source>. <year>2015</year>;<volume>112</volume>:<fpage>8738</fpage>–<lpage>8743</lpage>.<pub-id pub-id-type="pmid">26124093</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Kou</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>C</given-names></name></person-group>, . <article-title>A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>:<page-range>e81587</page-range>.</mixed-citation></ref><ref id="CIT0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name>, et al</person-group><article-title>A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein</article-title>. <source>J Virol</source>. <year>2014</year>;<volume>88</volume>:<fpage>7045</fpage>–<lpage>7053</lpage>.<pub-id pub-id-type="pmid">24719424</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>P</given-names></name>, et al</person-group><article-title>A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein</article-title>. <source>Cell Res</source>. <year>2015</year>;<volume>25</volume>:<fpage>1237</fpage>–<lpage>1249</lpage>.<pub-id pub-id-type="pmid">26391698</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Zuo</surname><given-names>T</given-names></name>, et al</person-group><article-title>Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein</article-title>. <source>Sci Transl Med</source>. <year>2014</year>;<volume>6</volume>:<fpage>234ra59</fpage>.</mixed-citation></ref><ref id="CIT0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>X-C</given-names></name>, <name name-style="western"><surname>Agnihothram</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Jiao</surname><given-names>Y</given-names></name>, et al</person-group><article-title>Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2014</year>;<volume>111</volume>:<fpage>E2018</fpage>–<lpage>E2026</lpage>.<pub-id pub-id-type="pmid">24778221</pub-id></mixed-citation><note><p><bold>•• A study of humanneutralizing antibodies against MERS-CoV.</bold></p></note></ref><ref id="CIT0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ying</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ju</surname><given-names>TW</given-names></name>, et al</person-group><article-title>Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies</article-title>. <source>J Virol</source>. <year>2014</year>;<volume>88</volume>:<fpage>7796</fpage>–<lpage>7805</lpage>.<pub-id pub-id-type="pmid">24789777</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Raj</surname><given-names>VS</given-names></name>, <name name-style="western"><surname>van Kuppeveld</surname><given-names>FJM</given-names></name>, et al</person-group><article-title>The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>:<fpage>9379</fpage>–<lpage>9383</lpage>.<pub-id pub-id-type="pmid">23785207</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Bagci</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Keith</surname><given-names>L</given-names></name>, et al</person-group><article-title>3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012</article-title>. <source>Virology</source>. <year>2016</year>;<volume>490</volume>:<fpage>49</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">26828465</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corti</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pedotti</surname><given-names>M</given-names></name>, et al</person-group><article-title>Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2015</year>;<volume>112</volume>:<fpage>10473</fpage>–<lpage>10478</lpage>.<pub-id pub-id-type="pmid">26216974</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luke</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name>, et al</person-group><article-title>Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo</article-title>. <source>Sci Transl Med</source>. <year>2016</year>;<volume>8</volume>:<fpage>326ra21</fpage>.</mixed-citation></ref><ref id="CIT0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>VS</given-names></name>, <name name-style="western"><surname>Mou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Smits</surname><given-names>SL</given-names></name>, et al</person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title>. <source>Nature</source>. <year>2013</year>;<volume>495</volume>:<fpage>251</fpage>–<lpage>254</lpage>.<pub-id pub-id-type="pmid">23486063</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name>, et al</person-group><article-title>Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26</article-title>. <source>Nature</source>. <year>2013</year>;<volume>500</volume>:<fpage>227</fpage>–<lpage>231</lpage>.<pub-id pub-id-type="pmid">23831647</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambeir</surname><given-names>A-M</given-names></name>, <name name-style="western"><surname>Durinx</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Scharpé</surname><given-names>S</given-names></name>, et al</person-group><article-title>Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV</article-title>. <source>Crit Rev Clin Lab Sci</source>. <year>2003</year>;<volume>40</volume>:<fpage>209</fpage>–<lpage>294</lpage>.<pub-id pub-id-type="pmid">12892317</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boonacker</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Van Noorden</surname><given-names>CJ</given-names></name></person-group><article-title>The multifunctional or moonlighting protein CD26/DPPIV</article-title>. <source>Eur J Cell Biol</source>. <year>2003</year>;<volume>82</volume>:<fpage>53</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">12647932</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>IF</given-names></name>, <name name-style="western"><surname>To</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>C-K</given-names></name>, et al</person-group><article-title>Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>;<volume>52</volume>:<fpage>447</fpage>–<lpage>456</lpage>.<pub-id pub-id-type="pmid">21248066</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luke</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Kilbane</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>JL</given-names></name>, et al</person-group><article-title>Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?</article-title><source>Ann Intern Med</source>. <year>2006</year>;<volume>145</volume>:<fpage>599</fpage>–<lpage>609</lpage>.<pub-id pub-id-type="pmid">16940336</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>-X-X</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>H-N</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H-B</given-names></name>, et al</person-group><article-title>Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma</article-title>. <source>Int J Infect Dis</source>. <year>2015</year>;<volume>41</volume>:<fpage>3</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">26482389</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>LK</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>BP</given-names></name></person-group><article-title>Successful treatment of avian influenza with convalescent plasma</article-title>. <source>Hong Kong Med J</source>. <year>2006</year>;<volume>12</volume>:<fpage>489</fpage>.</mixed-citation></ref><ref id="CIT0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mair-Jenkins</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Saavedra-Campos</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Baillie</surname><given-names>JK</given-names></name>, et al</person-group><article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis</article-title>. <source>J Infect Dis</source>. <year>2015</year>;<volume>211</volume>:<fpage>80</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">25030060</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arabi</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>Arifi</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Balkhy</surname><given-names>HH</given-names></name>, et al</person-group><article-title>Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection</article-title>. <source>Ann Intern Med</source>. <year>2014</year>;<volume>160</volume>:<fpage>389</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">24474051</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapoor</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pringle</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name>, et al</person-group><article-title>Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus (MERS-CoV) into the United States</article-title>. <source>Clin Infect Dis An Off Publ Infect Dis Soc Am</source>. <year>2014</year>;<volume>59</volume>:<fpage>1511</fpage>–<lpage>1518</lpage>.</mixed-citation></ref><ref id="CIT0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arabi</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Balkhy</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hajeer</surname><given-names>AH</given-names></name>, et al</person-group><article-title>Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol</article-title>. <source>Springerplus</source>. <year>2015</year>;<volume>4</volume>:<fpage>709</fpage>.<pub-id pub-id-type="pmid">26618098</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alshukairi</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Khalid</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>WA</given-names></name>, et al</person-group><article-title>Antibody response and disease severity in healthcare worker MERS survivors</article-title>. <source>Emerg Infect Dis</source>. <year>2016</year>;<volume>22</volume> DOI:<pub-id pub-id-type="doi">10.3201/eid2206.160010</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drosten</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Meyer</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Müller</surname><given-names>MA</given-names></name>, et al</person-group><article-title>Transmission of MERS-coronavirus in household contacts</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>828</fpage>–<lpage>835</lpage>.<pub-id pub-id-type="pmid">25162889</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corman</surname><given-names>VM</given-names></name>, <name name-style="western"><surname>Albarrak</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Omrani</surname><given-names>AS</given-names></name>, et al</person-group><article-title>Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection</article-title>. <source>Clin Infect Dis</source>. <year>2015</year>.</mixed-citation><note><p><bold>•• A study of viral shedding of MERS-CoV.</bold></p></note></ref><ref id="CIT0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>WB</given-names></name>, <name name-style="western"><surname>Perera</surname><given-names>RAPM</given-names></name>, <name name-style="western"><surname>Choe</surname><given-names>PG</given-names></name>, et al</person-group><article-title>Kinetics of serologic responses to mers coronavirus infection in humans, South Korea</article-title>. <source>Emerg Infect Dis</source>. <year>2015</year>;<volume>21</volume>:<fpage>2186</fpage>–<lpage>2189</lpage>.<pub-id pub-id-type="pmid">26583829</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arabi</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>Hajeer</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Luke</surname><given-names>T</given-names></name>, et al</person-group><article-title>Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia</article-title>. <source>Emerg Infect Dis</source>. <year>2016</year>;<volume>22</volume>:<fpage>1554</fpage>–<lpage>1561</lpage>.<pub-id pub-id-type="pmid">27532807</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>B</given-names></name>, et al</person-group><article-title>Clinical recommendations from an observational study on MERS: glucocorticoids was benefit in treating SARS patients</article-title>. <source>Int J Clin Exp Med</source>. <year>2016</year>;<volume>9</volume>:<fpage>8865</fpage>–<lpage>8873</lpage>.</mixed-citation></ref><ref id="CIT0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Auyeung</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>W</given-names></name>, et al</person-group><article-title>The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study</article-title>. <source>J Infect</source>. <year>2005</year>;<volume>51</volume>:<fpage>98</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">16038758</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Allen Chan</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>DS</given-names></name>, et al</person-group><article-title>Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients</article-title>. <source>J Clin Virol</source>. <year>2004</year>;<volume>31</volume>:<fpage>304</fpage>–<lpage>309</lpage>.<pub-id pub-id-type="pmid">15494274</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The Who Mers-Cov Research Group</collab></person-group><article-title>State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans</article-title>. <source>PLoS Curr</source>. <year>2013</year>;<volume>5</volume>:<fpage>1</fpage>–<lpage>30</lpage>.</mixed-citation></ref><ref id="CIT0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belouzard</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Millet</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Licitra</surname><given-names>BN</given-names></name>, et al</person-group><article-title>Mechanisms of coronavirus cell entry mediated by the viral spike protein</article-title>. <source>Viruses</source>. <year>2012</year>;<volume>4</volume>:<fpage>1011</fpage>–<lpage>1033</lpage>.<pub-id pub-id-type="pmid">22816037</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyall</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Coleman</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Hart</surname><given-names>BJ</given-names></name>, et al</person-group><article-title>Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>:<fpage>4885</fpage>–<lpage>4893</lpage>.<pub-id pub-id-type="pmid">24841273</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uyeki</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Erlandson</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Korch</surname><given-names>G</given-names></name>, et al</person-group><article-title>Development of medical countermeasures to Middle East respiratory syndrome coronavirus</article-title>. <source>Emerg Infect Dis</source>. <year>2016</year>;<volume>22</volume> DOI:<pub-id pub-id-type="doi">10.3201/eid2207.160022</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakamoto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tanaka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Morimoto</surname><given-names>S</given-names></name></person-group><article-title>Towards the prophylactic and therapeutic use of human neutralizing monoclonal antibodies for Middle East respiratory syndrome coronavirus (MERS-CoV)</article-title>. <source>Ann Transl Med</source>. <year>2015</year>;<volume>3</volume>:<fpage>35</fpage>.<pub-id pub-id-type="pmid">25815296</pub-id></mixed-citation><note><p><bold>• A study of use of human neutralizing monoclonal antibodies for MERS-CoV.</bold></p></note></ref><ref id="CIT0075"><label>75.</label><mixed-citation publication-type="web"><person-group person-group-type="author"><name name-style="western"><surname>Modjarrad</surname><given-names>K</given-names></name></person-group><article-title>Research and development activities for Middle East respiratory syndrome</article-title>: <source>The Current Landscape</source>. <year>n d.</year><date-in-citation>[cited 2016 <month>11</month><day>25</day>]</date-in-citation><comment>Available from:</comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/research-and-development/mers-landscape.pdf">http://www.who.int/csr/research-and-development/mers-landscape.pdf</ext-link></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0013210 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0013210 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |